Global Pneumonia Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pneumonia Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.
Pneumonia Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumonia Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Pneumonia and Meningitis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pneumonia Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pneumonia Vaccine key manufacturers include Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc. and CSL Limited, etc. Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc. are top 3 players and held % sales share in total in 2022.
Pneumonia Vaccine can be divided into Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23) and Other,, etc. Pneumococcal Conjugate Vaccine (PCV13) is the mainstream product in the market, accounting for % sales share globally in 2022.
Pneumonia Vaccine is widely used in various fields, such as Pneumonia, Meningitis and Sepsis,, etc. Pneumonia provides greatest supports to the Pneumonia Vaccine industry development. In 2022, global % sales of Pneumonia Vaccine went into Pneumonia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumonia Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer Inc.
Glaxosmithkline Plc.
Merck & Co., Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Johnson & Johnson
Astellas Pharma Inc.
Astrazeneca Plc.
CSL Limited
Emergent Biosolutions
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
Pneumonia
Meningitis
Sepsis
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pneumonia Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumonia Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumonia Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumonia Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumonia Vaccine introduction, etc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pneumonia Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Pneumonia Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumonia Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Pneumonia and Meningitis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pneumonia Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pneumonia Vaccine key manufacturers include Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc. and CSL Limited, etc. Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc. are top 3 players and held % sales share in total in 2022.
Pneumonia Vaccine can be divided into Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23) and Other,, etc. Pneumococcal Conjugate Vaccine (PCV13) is the mainstream product in the market, accounting for % sales share globally in 2022.
Pneumonia Vaccine is widely used in various fields, such as Pneumonia, Meningitis and Sepsis,, etc. Pneumonia provides greatest supports to the Pneumonia Vaccine industry development. In 2022, global % sales of Pneumonia Vaccine went into Pneumonia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumonia Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer Inc.
Glaxosmithkline Plc.
Merck & Co., Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Johnson & Johnson
Astellas Pharma Inc.
Astrazeneca Plc.
CSL Limited
Emergent Biosolutions
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
Segment by Application
Pneumonia
Meningitis
Sepsis
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pneumonia Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumonia Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumonia Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumonia Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumonia Vaccine introduction, etc. Pneumonia Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pneumonia Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices